

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

Luping Lin^{1,2}, Amit J Sabnis¹⁻³, Elton Chan^{1,2}, Victor Olivas^{1,2}, Lindsay Cade^{1,2}, Evangelos Pazarentzos^{1,2}, Saurabh Asthana^{1,2}, Dana Neel^{1,2}, Jenny Jiacheng Yan^{1,2}, Xinyuan Lu^{1,2}, Luu Pham^{1,2}, Mingxue M Wang^{1,2}, Niki Karachaliou⁴, Maria Gonzalez Cao⁴, Jose Luis Manzano⁵, Jose Luis Ramirez⁶, Jose Miguel Sanchez Torres⁷, Fiamma Buttitta⁸, Charles M Rudin^{9,10}, Eric A Collisson^{1,2}, Alain Algazi^{1,2}, Eric Robinson¹¹, Iman Osman¹¹, Eva Muñoz-Couselo¹², Javier Cortes¹², Dennie T Frederick^{13,14}, Zachary A Cooper^{15,16}, Martin McMahon², Antonio Marchetti⁸, Rafael Rosell⁴, Keith T Flaherty^{13,14}, Jennifer A Wargo^{15,16} & Trevor G Bivona^{1,2}

Resistance to RAF- and MEK-targeted therapy is a major clinical challenge¹⁻⁴. RAF and MEK inhibitors are initially but only transiently effective in some but not all patients with *BRAF* gene mutation and are largely ineffective in those with *RAS* gene mutation because of resistance⁵⁻¹⁴. Through a genetic screen in *BRAF*-mutant tumor cells, we show that the Hippo pathway effector YAP (encoded by *YAP1*) acts as a parallel survival input to promote resistance to RAF and MEK inhibitor therapy. Combined YAP and RAF or MEK inhibition was synthetically lethal not only in several *BRAF*-mutant tumor types but also in *RAS*-mutant tumors. Increased YAP in tumors harboring *BRAF* V600E was a biomarker of worse initial response to RAF and MEK inhibition in patients, establishing the clinical relevance of our findings. Our data identify YAP as a new mechanism of resistance to RAF- and MEK-targeted therapy. The findings unveil the synthetic lethality of combined suppression of YAP and RAF or MEK as a promising strategy to enhance treatment response and patient survival.

Oncogenic activation of RAF-MEK-ERK (mitogen-activated protein kinase (MAPK) pathway) signaling frequently occurs in human cancers, often through somatic activating mutations in *BRAF* or *RAS* genes. MAPK pathway-targeted therapies (RAF and MEK inhibitors) have been deployed in patients with *BRAF*- and *RAS*-mutant tumors and have been demonstrated to have clinical efficacy in melanoma and non-small cell lung cancer (NSCLC) harboring *BRAF* V600E¹⁻⁴, but responses are variable, incomplete and transient because of

resistance¹⁻⁴. Furthermore, some patients with *BRAF* V600E-mutant melanoma or NSCLC and almost all patients with *BRAF* V600E-mutant colorectal or thyroid cancer do not initially respond to *BRAF* inhibitor therapy^{1-4,8-15}. Similarly, MAPK pathway inhibition with MEK inhibitor therapy is largely ineffective in individuals with mutant *RAS* because of primary resistance^{5-7,16,17}. Thus, there is an urgent need to uncover the molecular targets that limit the response to RAF- and MEK-targeted therapy in both *BRAF*- and *RAS*-mutant tumors to develop new therapeutic strategies to enhance treatment response and patient survival.

To uncover new genetic modifiers of the response to RAF-targeted therapy in human cancer, we conducted a pooled short hairpin RNA (shRNA) screen in human NSCLC cells harboring *BRAF* V600E (HCC364 cells) that are dependent on oncogenic *BRAF* for growth¹¹. Our goal was to identify genes that, when silenced, enhanced the response to RAF inhibitor. We screened 27,500 shRNAs targeting 5,046 signaling components (Supplementary Table 1). After infecting HCC364 cells with lentiviruses expressing the shRNA library and subjecting them to selection, we treated the cells with the selective *BRAF* inhibitor vemurafenib or with vehicle control (Fig. 1a). We quantified the abundance of each barcoded hairpin to identify shRNAs that were selectively depleted during treatment with vemurafenib but not vehicle (Fig. 1a), as described previously^{12,18}. The Hippo signaling pathway component *YAP1* was the best-scoring hit in the screen, as all six *YAP1*-targeted shRNAs present in the screening library were depleted during treatment with vemurafenib but not vehicle (Fig. 1b,c, Supplementary Fig. 1 and Supplementary Table 2).

¹Department of Medicine, University of California, San Francisco, San Francisco, California, USA. ²Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA. ³Department of Pediatrics, Division of Pediatric Hematology and Oncology, University of California, San Francisco, San Francisco, California, USA. ⁴Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain. ⁵Medical Oncology Service, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain. ⁶Translational Oncology Laboratory, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Fundació Institut Recerca Germans Trias i Pujol (IGTP), Barcelona, Spain. ⁷Medical Oncology Service, Hospital Universitario de La Princesa, Madrid, Spain. ⁸Center for Predictive Molecular Medicine, University Foundation, Chieti-Pescara, Chieti, Italy. ⁹Molecular Chemistry and Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA. ¹⁰Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA. ¹¹Ronald O. Perleman Department of Dermatology, Medicine and Urology, New York University Cancer Institute, New York, New York, USA. ¹²Vall d'Hebron Institute of Oncology, Barcelona, Spain. ¹³Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. ¹⁴Massachusetts General Hospital Comprehensive Cancer Center, Boston, Massachusetts, USA. ¹⁵Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas, USA. ¹⁶Department of Genomic Medicine, MD Anderson Cancer Center, Houston, Texas, USA. Correspondence should be addressed to T.G.B. (tbivona@medicine.ucsf.edu).

Received 6 June 2014; accepted 15 January 2015; published online 9 February 2015; doi:10.1038/ng.3218




Figure 1 A pooled shRNA screen in BRAF-mutant human lung cancer cells identifies new modifiers of the RAF inhibitor response including YAP. (a) Summary of the pooled shRNA screening strategy in BRAF-mutant human lung cancer cells. (b, c) Primary screen data showing gene targets (b) and shRNAs depleted specifically upon vemurafenib treatment (c), highlighting *YAP1* in red. shYAP1, shRNA to *YAP1*; shLUC, shRNA to the luciferase gene. (d) Validation of the effects of *YAP1* knockdown on sensitivity to vemurafenib in HCC364 BRAF-mutant lung cancer cells (both IC₅₀ and cell viability results are shown). The inset shows the effects of each *YAP1* shRNA by immunoblot for YAP protein expression. SCR, scrambled control shRNA. Data are shown as means ± s.e.m. (*n* = 3 biological replicates). (e) Validation of the effects of *YAP1* knockdown on sensitivity to trametinib in HCC364 BRAF-mutant lung cancer cells (IC₅₀, cell viability and maximal growth inhibition results are shown). Data are shown as means ± s.e.m. (*n* = 3 biological replicates). (f) Effects of *YAP1* knockdown on sensitivity to vemurafenib and trametinib in HCC364 BRAF-mutant lung cancer cells (cell growth by crystal violet staining assays is shown, with quantification for each condition relative to cells expressing the scrambled control shRNA treated with DMSO control). (g) Effects of *YAP1* knockdown on sensitivity to trametinib in Cal-12T BRAF-mutant (non-V600E) lung cancer cells (IC₅₀, cell viability and maximal growth inhibition results are shown). Data are shown as means ± s.e.m. (*n* = 3 biological replicates).

We therefore hypothesized that the encoded YAP protein is a new determinant of the response to RAF inhibitor and that YAP inhibition might enhance the efficacy of RAF-targeted therapy.

We used independent shRNAs to knock down *YAP1* in HCC364 cells. *YAP1* silencing enhanced sensitivity to vemurafenib with little effect in vehicle-treated cells, confirming the initial screening results (Fig. 1d, f, Supplementary Fig. 1 and Supplementary Table 3). As BRAF activates MEK and MEK inhibitor monotherapy has incomplete efficacy in patients with BRAF V600E-mutant tumors^{1,3}, we tested whether *YAP1* silencing enhanced the response to MEK inhibitor in HCC364 cells. *YAP1* knockdown enhanced sensitivity to the MEK inhibitor trametinib in this system (Fig. 1e, f and Supplementary Table 3). *YAP1* suppression enhanced not only sensitivity to trametinib (IC₅₀, half-maximal inhibition concentration) but also the degree to which maximal growth inhibition was achieved by MEK inhibition (Fig. 1e and Supplementary Table 4). These effects of

YAP1 silencing were specific to targeted inhibition of RAF-MEK signaling, as *YAP1* knockdown had no effect on sensitivity to cytotoxic chemotherapy (Supplementary Fig. 2). We found that the transcriptional output of YAP is likely critical for regulation of the response to RAF- and MEK-targeted therapy, as silencing either of the Hippo-YAP pathway transcription factor effectors *TEAD2* and *TEAD4* (encoding TEA domain (TEAD) family members 2 and 4)^{19,20} phenocopied the effects of *YAP1* suppression on sensitivity to RAF and MEK inhibitors in HCC364 cells (Supplementary Fig. 2). Moreover, we observed nuclear YAP expression in these BRAF-mutant cells in cellular fractionation studies (Supplementary Fig. 3). We further found that stable overexpression of either *YAP1* or its paralog *TAZ*¹⁹ substantially decreased sensitivity to vemurafenib and trametinib in HCC364 cells (Supplementary Fig. 4).

As MEK inhibitor therapy is more effective than RAF inhibitor therapy in some tumor cells with non-V600E forms of mutant BRAF¹¹, we tested whether *YAP1* silencing enhanced sensitivity to trametinib

in Cal-12T human NSCLC cells that exhibit MEK-ERK activation but harbor a *BRAF* mutation encoding a G466V substitution. *YAP1* depletion enhanced the efficacy of the MEK inhibitor in Cal-12T cells, indicating that the effects of *YAP1* suppression in response to MEK inhibitor are not restricted to V600E forms of mutant *BRAF* (Fig. 1g and Supplementary Tables 3 and 4). Collectively, these data demonstrate that YAP modulates the response to targeted inhibition of RAF signaling in human NSCLC models.

We next investigated whether YAP regulates the response to targeted inhibition of *BRAF* signaling in other *BRAF*-mutant tumor histologies, using human melanoma, colon and thyroid cancer cell lines with endogenous *BRAF* mutation encoding the V600E substitution. *YAP1* suppression enhanced the efficacy of both vemurafenib and trametinib in the A2058 and WM793 melanoma cell lines, the HT29 and WiDr colon cancer cell lines, and the KHM-5M and HTC/C3 thyroid cancer cell lines, all harboring *BRAF* V600E, without significantly affecting vehicle-treated cells (Fig. 2a,b, Supplementary Figs. 3, 5 and 6, and Supplementary Tables 3 and 4). We again observed nuclear YAP expression in these other *BRAF*-mutant cell lines (Supplementary Fig. 3). Extending our *in vitro* findings, we found that silencing *YAP1* enhanced the response to not only vemurafenib but also trametinib *in vivo* in A2058 melanoma xenografts, without significantly affecting tumor growth in vehicle-treated tumors (Fig. 2c and Supplementary Fig. 7). *YAP1* suppression led to tumor regression upon trametinib treatment in this *in vivo* system (Fig. 2c and Supplementary Fig. 7). Additionally, we found that *YAP1*

silencing enhanced the response to RAF and MEK inhibitors *in vivo* in HT29 colon cancer xenografts harboring *BRAF* V600E, without significantly affecting tumor growth in vehicle-treated tumors (Fig. 2d and Supplementary Fig. 7). These data show that *YAP1* suppression enhances RAF and MEK inhibitor efficacy in many *BRAF*-mutant tumor types, not only in cells with intrinsic sensitivity but also in those with intrinsic resistance to monotherapy with RAF or MEK inhibitor (Fig. 2, Supplementary Figs. 5, 6 and 7, and Supplementary Tables 3 and 4). *YAP1* silencing even overcame intrinsic resistance to RAF and MEK inhibitors in A2058 and KHM-5M cells in which no effect from inhibition of epidermal growth factor receptor (EGFR), which can promote resistance to RAF inhibitor in some tumors with *BRAF* V600E^{8,12}, was observed (Supplementary Fig. 8). These data indicate a distinct and broad role for YAP in promoting resistance to RAF and MEK inhibition across a wide spectrum of *BRAF*-mutant tumors.

We next explored whether YAP regulates the response to MAPK pathway inhibition in tumor cells with oncogenic RAS, which drives tumor growth, in part, through MEK-ERK signaling²¹. No effective targeted therapies exist for patients with tumors having mutant RAS, with MEK inhibitor therapy exhibiting limited efficacy^{5-7,16,17}. We investigated whether *YAP1* suppression could enhance the response to MEK inhibitor in RAS-mutant tumors. Silencing *YAP1* enhanced the efficacy of trametinib in multiple *KRAS*- and *NRAS*-mutant human NSCLC, melanoma and pancreatic adenocarcinoma models and across several distinct mutant alleles of *RAS* genes (Fig. 2e,




Figure 2 YAP regulates the response to RAF and MEK inhibitors in multiple *BRAF*-mutant tumor types. (a,b) Effects of *YAP1* knockdown on sensitivity to vemurafenib (a) and trametinib (b) in the indicated *BRAF*-mutant cell lines, shown as relative IC₅₀ (data are shown as means ± s.e.m. for all cell viability data; *n* = 3 biological replicates). (c) Effects of *YAP1* knockdown (shYAP1-1) on the efficacy of vemurafenib (PLX4720) and trametinib in A2058 melanoma xenografts encoding *BRAF* V600E (data are shown as means ± s.e.m.; *n* = 8–12 tumors/group). (d) Effects of *YAP1* knockdown on the efficacy of vemurafenib (PLX4720) and trametinib in HT29 colon cancer xenografts encoding *BRAF* V600E (data are shown as means ± s.e.m.; *n* = 8–12 tumors/group). (e) Effects of *YAP1* knockdown on sensitivity to trametinib in the indicated *RAS*-mutant tumor cell lines, shown as relative IC₅₀ (data are shown as means ± s.e.m. for all cell viability data; *n* = 3 biological replicates). (f) Effects of *YAP1* knockdown on the efficacy of trametinib in MOR/CPR *RAS*-mutant NSCLC xenografts (data are shown as means ± s.e.m.; *n* = 8–12 tumors/group). NS, not significant; *P* < 0.05 for IC₅₀ differences between each *YAP1* shRNA and scrambled shRNA control in a, b and e, Student *t* test.

Supplementary Figs. 5, 9 and 10, and Supplementary Tables 3 and 4. *YAP1* suppression enhanced the response to trametinib, as measured by IC_{50} across these models, but had only modest effects on maximal growth inhibition upon MEK inhibitor treatment in RAS-mutant melanoma and pancreatic adenocarcinoma cells (Fig. 2e and Supplementary Fig. 5). We again observed nuclear YAP expression

in these RAS-mutant cell lines (Supplementary Fig. 3). We confirmed these findings *in vivo* by demonstrating that *YAP1* silencing enhanced the response to trametinib in MOR/CPR xenograft tumors encoding KRAS G12C (Fig. 2f and Supplementary Fig. 7). These data identify combined inhibition of YAP and MEK as a promising strategy to enhance treatment response in patients with mutant RAS.




Figure 3 Synthetic lethality and synergistic induction of apoptosis with concurrent inhibition of YAP and oncogenic MAPK signaling. (a–h) Effects of *YAP1* knockdown on apoptosis induced by treatment with vemurafenib (top) or trametinib (bottom) in HCC364 BRAF-mutant lung cancer cells as measured by caspase-3 and caspase-7 activation (a) and the levels of cleaved PARP by immunoblot analysis (b); in A2058 BRAF-mutant melanoma cells as measured by caspase-3 and caspase-7 activation (c) and the levels of cleaved PARP by immunoblot analysis (d); in HT29 BRAF-mutant colon cancer cells as measured by caspase-3 and caspase-7 activation (e) and the levels of cleaved PARP by immunoblot analysis (f); and in KHM-5M BRAF-mutant thyroid cancer cells as measured by caspase-3 and caspase-7 activation (g) and the levels of cleaved PARP by immunoblot analysis (h). Data are shown as means \pm s.e.m.; $n = 3$ biological replicates.

Caspase activation was normalized to levels in cells treated with DMSO vehicle. D, DMOS; V, vemurafenib; T, trametinib. (i) Effects of *YAP1* suppression and treatment with vemurafenib or trametinib on BCL-xL levels in HCC364 cells. Levels of BCL-xL were measured by quantitative RT-PCR (top) and immunoblot analysis (bottom). Data are shown as means \pm s.e.m.; $n = 3$ biological replicates. Comparisons were to levels in cells expressing scrambled shRNA and treated with DMSO. (j) Effects of pharmacological inhibition of BCL-xL using ABT-263 on sensitivity to vemurafenib or trametinib in HCC364 BRAF-mutant lung cancer cells, A2058 BRAF-mutant melanoma cells and HT29 BRAF-mutant colon cancer cells. Data are shown as means \pm s.e.m.; $n = 3$ biological replicates. Comparisons were to levels in corresponding cells treated with DMSO. P values are indicated for statistical analysis.




Figure 4 Increased YAP levels in human tumor specimens encoding BRAF V600E is a biomarker of worse response to RAF inhibitor in patients. **(a)** Quantification of the levels of YAP in human NSCLC ($n = 13$) and melanoma ($n = 29$) specimens encoding BRAF V600E, KRAS-mutant NSCLC specimens ($n = 23$) and human tumor specimens with wild-type BRAF and KRAS (WT; NSCLC; $n = 14$), as measured by immunohistochemistry with a validated antibody to YAP and scoring of the staining as low, intermediate or high. **(b)** Quantification of YAP levels in melanoma or NSCLC specimens encoding BRAF V600E from patients with either a confirmed complete response (melanoma CR, $n = 6$) or an incomplete response (melanoma IR, $n = 29$; NSCLC IR, $n = 5$; incomplete response includes either a partial response or stable disease by RECIST criteria) to initial treatment with a RAF inhibitor (vemurafenib, dabrafenib or LGX818; $n = 16$) or to combined RAF and MEK inhibitor treatment (dabrafenib and trametinib or LGX818 and MEK162; $n = 19$) ($P = 0.008$ distinguishing the proportion of complete response from incomplete response among melanomas with high YAP levels). YAP immunohistochemistry analysis was conducted as in **a**. **(c)** YAP functions via BCL-xL as a parallel input to suppress apoptosis and promote survival, protecting BRAF- and RAS-mutant tumor cells from death (left). RAF- and MEK-targeted therapy is therefore ineffective or cytostatic, resulting in an incomplete tumor response (middle). YAP suppression lowers the threshold for the induction of apoptosis upon RAF or MEK inhibition, promoting a complete response (right). P, phosphorylation; RAS*, mutant RAS.

Our findings extend recent studies indicating that YAP regulates *KRAS* oncogene dependence in some tumor types^{22–24} by establishing that *YAP1* suppression enhances the response to MEK inhibitor in multiple tumor histologies and functions across several different forms of oncogenic MAPK signaling.

We next investigated the mechanism through which YAP regulates the response to RAF- and MEK-targeted therapy. As *YAP1* silencing profoundly impaired cell viability, specifically upon treatment with RAF or MEK inhibitor, and previous work indicates that YAP can regulate apoptosis^{22,24–26}, we reasoned that suppression of YAP together with RAF-MEK signaling might be synthetically lethal. Indeed, we found that *YAP1* knockdown promoted apoptosis, as measured by both the induction of caspase-3 and caspase-7 activity and PARP cleavage, upon treatment with either RAF or MEK inhibitor that alone was insufficient to induce apoptosis in NSCLC (Fig. 3a,b), melanoma (Fig. 3c,d), colon cancer (Fig. 3e,f and Supplementary Fig. 11) and thyroid cancer (Fig. 3g,h) models harboring BRAF V600E. *YAP1* silencing also enhanced apoptosis upon treatment with MEK inhibitor, which by itself did not induce cell death in RAS-mutant NSCLC models, albeit more modestly than in many BRAF-mutant models

(Supplementary Fig. 11). These findings show the synthetic lethality of combined suppression of YAP and RAF-MEK signaling.

We reasoned that YAP might enhance the expression of an anti-apoptotic factor to promote survival and resistance to RAF and MEK inhibitors. YAP can transcriptionally upregulate the expression of specific antiapoptotic components, including the BCL2 family member protein BCL-xL (encoded by *BCL2L1*) in some cell types²⁷. Therefore, we hypothesized that YAP might control the threshold for apoptosis induction during RAF- and MEK-targeted therapy by promoting BCL-xL expression as a parallel survival input in tumor cells with oncogenic BRAF. Indeed, *YAP1* suppression resulted in decreased expression of BCL-xL, specifically in the context of treatment with either vemurafenib or trametinib in HCC364 NSCLC, A2058 melanoma, HT29 colon cancer and KHM-5M thyroid cancer cells (Fig. 3i and Supplementary Fig. 12). These data show that YAP and RAF-MEK signaling function in parallel to regulate BCL-xL levels, which might ensure that the threshold for the induction of apoptosis is achieved only with inhibition of both YAP and RAF-MEK signaling.

We confirmed the relevance of BCL-xL function downstream of YAP, establishing that BCL-xL overexpression rescued the effect

of *YAP1* silencing on the response to RAF and MEK inhibitors in HCC364 cells (**Supplementary Fig. 13**). These data indicate that BCL-xL is a critical effector by which YAP promotes resistance to RAF or MEK inhibition. Consistent with these observations and those of others²⁸, pharmacological BCL-xL inhibition using ABT-263 (navitoclax) enhanced the efficacy of treatment with either RAF or MEK inhibitor in several tumor cell lines harboring BRAF V600E, including NSCLC (HCC364), melanoma (A2058) and colon cancer (HT29) models (**Fig. 3j**). Treatment with BCL-xL inhibitor also enhanced sensitivity to trametinib in RAS-mutant NSCLC cells (**Supplementary Fig. 11**). These effects of ABT-263 treatment were phenocopied by treatment with another BCL-xL inhibitor, TW37 (**Supplementary Fig. 11**). These data indicate that YAP acts as a parallel survival input via BCL-xL to promote resistance to RAF and MEK inhibitors, extending recent findings linking BCL-xL with the response to MEK inhibitor in some KRAS-mutant tumors^{29,30}.

To further explore the synthetic lethal relationship between YAP and RAF or MEK inhibition, we conducted unbiased transcriptional profiling in HCC364 cells harboring BRAF V600E in which YAP and MEK were suppressed individually or concurrently. These profiling data showed few significant changes in gene expression with silencing of *YAP1* alone (adjusted *P* value < 0.05 and at least 40% decreased or at least 66% increased expression, compared to the control) (**Supplementary Table 5**), consistent with our functional studies indicating that *YAP1* silencing has a weaker impact on cell viability (**Fig. 1** and **Supplementary Fig. 1**). Treatment with trametinib led to differential expression of more genes, consistent with the important role of BRAF-MEK signaling in these cells (**Supplementary Table 5**). Silencing *YAP1* together with trametinib treatment similarly led to differential expression of a substantial number of genes, with evidence of coregulation of some genes, including *BCL2L1* (**Supplementary Table 5**). Pathway analysis of the genes that were significantly altered specifically by combined inhibition of YAP and MEK (such as *BCL2L1*) indicated an enrichment of genes involved in apoptosis (**Supplementary Fig. 14**). These findings offer additional insight into the role of BCL-xL and the synthetic lethality of simultaneous suppression of YAP and RAF-MEK signaling.

We next sought to determine the clinical relevance of our findings. We hypothesized that YAP might be upregulated in some BRAF- or RAS-mutant human tumors and that this upregulation might promote resistance to RAF and MEK inhibitors in patients. We therefore measured YAP levels in primary human tumor specimens obtained from patients with NSCLC (*n* = 13) or melanoma (*n* = 35) encoding BRAF V600E, from patients with KRAS-mutant NSCLC (*n* = 23) or from patients with NSCLC with wild-type BRAF and KRAS (*n* = 14). We observed high levels of YAP in the majority of the tumors encoding BRAF V600E (NSCLC and melanoma) and the KRAS-mutant NSCLC tumors and lower levels of YAP in tumors with wild-type BRAF and KRAS (NSCLC), as measured by immunohistochemistry using an antibody to YAP (**Fig. 4a** and **Supplementary Fig. 15**). These data show that YAP is upregulated in some BRAF- and RAS-mutant human tumors. As MEK inhibitor monotherapy is largely ineffective in patients with KRAS-mutant tumors¹⁷, these findings suggest that increased YAP levels in these tumors might contribute to primary resistance to MEK inhibition.

We next assessed whether YAP expression was inversely correlated with the initial response to RAF and MEK inhibition in patients with BRAF V600E (*n* = 35). We measured YAP levels by immunohistochemistry in melanoma specimens harboring BRAF V600E from patients (*n* = 35) with either a confirmed complete response or an incomplete response (including either a partial response or stable

disease by RECIST (Response Evaluation Criteria in Solid Tumors) criteria) to monotherapy with a BRAF inhibitor (vemurafenib, dabrafenib or LGX818; *n* = 16) or to combined RAF and MEK inhibitor treatment (dabrafenib and trametinib or LGX818 and MEK162; *n* = 19). Patients with melanoma harboring BRAF V600E who had a complete response to therapy exhibited lower YAP expression in the pretreatment tumor samples (**Fig. 4b** and **Supplementary Table 6**). Conversely, patients who had an incomplete response to therapy had higher YAP expression in the baseline tumor samples (**Fig. 4b** and **Supplementary Table 6**). We also analyzed YAP expression in NSCLC tumors with BRAF V600E obtained from patients (*n* = 5) before investigational treatment with dabrafenib, which resulted in an incomplete response in each patient. All but one of these pretreatment NSCLC specimens exhibited high YAP expression (**Fig. 4b** and **Supplementary Table 6**). Taken together, these data suggest that increased YAP levels are a biomarker of decreased response to RAF or MEK inhibitor in patients with BRAF-mutant tumors.

We also assessed YAP levels in melanomas obtained from patients at the time of progression on RAF or MEK inhibitor therapy after an initial response to test the hypothesis that YAP might contribute to acquired resistance. We examined YAP expression by immunohistochemistry in an additional 32 paired melanoma specimens with BRAF V600E obtained from 16 patients both before RAF or MEK inhibitor treatment and upon the development of acquired resistance. As the majority of the pretreatment melanoma specimens encoding BRAF V600E from patients harbored high baseline YAP levels (**Supplementary Table 7**), we examined whether YAP levels were higher at the time of progression in the subset of patients whose pretreatment tumors had low or intermediate YAP levels (25%, 4/16 cases; **Supplementary Fig. 15** and **Supplementary Table 7**). We found increased YAP levels in each paired tumor obtained at acquired resistance in comparison to the matched pretreatment specimen (**Supplementary Fig. 15** and **Supplementary Table 7**). These findings further suggest that increased YAP levels might limit the clinical efficacy of RAF and MEK inhibitors.

All together, our findings unveil the synthetic lethality of concurrent inhibition of YAP and RAF-MEK signaling (**Fig. 4c**) and augment findings indicating an emerging role for YAP in tumorigenesis across several different tumor types^{22–24,31,32}. The data show unanticipated functional cross-talk between YAP and RAF-MEK signaling. Our findings uncover a new, promising polytherapeutic strategy to enhance the efficacy of RAF and MEK inhibitors and survival in patients with a broad range of BRAF- and RAS-mutant tumors.

METHODS

Methods and any associated references are available in the [online version of the paper](#).

Accession codes. Transcriptome analysis (RNA sequencing) of HCC364 cells in the context of YAP and MEK suppression, individually or concurrently, [GSE64550](#).

Note: Any Supplementary Information and Source Data files are available in the online version of the paper.

ACKNOWLEDGMENTS

We thank G. Bollag and P. Lin (Plexxikon) for providing PLX4720. We thank J. Weissman and members of the Bivona laboratory for critical review of the manuscript. The authors acknowledge funding support (to T.G.B.) from the following sources: US National Institutes of Health (NIH) Director's New Innovator Award (DP2CA174497), the Howard Hughes Medical Institute (Collaborative Innovation Award), the Doris Duke Charitable Foundation, the American Lung Association, the National Lung Cancer Partnership, the Addario and Van Auken

Private Foundations, the Sidney Kimmel Foundation for Cancer Research and the Searle Scholars Program. The authors also acknowledge funding from La Caixa Foundation (to R.R.) and from US NIH grant R01CA131261 (to M.M.).

AUTHOR CONTRIBUTIONS

L.L., E.C., A.J.S., V.O., D.N., J.J.Y., E.P., X.L., M.M.W., L.P. and E.A.C. conducted all experiments and/or analyzed data. L.C. and S.A. conducted the analysis of the shRNA screening data. M.M. provided cell lines and analyzed data. N.K., M.G.C., J.L.M., J.L.R., J.M.S.T., F.B., C.M.R., A.A., E.R., I.O., E.C., E.M.-C., J.C., A.M., R.R., D.T.F., Z.A.C., K.T.F. and J.A.W. provided clinical samples and data. All authors contributed to the design of experiments and to data analysis and interpretation. T.G.B., L.L. and A.J.S. wrote the manuscript with input from all coauthors.

COMPETING FINANCIAL INTERESTS

The authors declare competing financial interests: details are available in the [online version of the paper](#).

Reprints and permissions information is available online at <http://www.nature.com/reprints/index.html>.

- Flaherty, K.T. *et al.* Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. *N. Engl. J. Med.* **367**, 1694–1703 (2012).
- Flaherty, K.T. *et al.* Inhibition of mutated, activated BRAF in metastatic melanoma. *N. Engl. J. Med.* **363**, 809–819 (2010).
- Flaherty, K.T. *et al.* Improved survival with MEK inhibition in BRAF-mutated melanoma. *N. Engl. J. Med.* **367**, 107–114 (2012).
- Sosman, J.A. *et al.* Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. *N. Engl. J. Med.* **366**, 707–714 (2012).
- Adjei, A.A. *et al.* Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. *J. Clin. Oncol.* **26**, 2139–2146 (2008).
- Jänne, P.A. *et al.* Selumetinib plus docetaxel for *KRAS*-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. *Lancet Oncol.* **14**, 38–47 (2013).
- Migliardi, G. *et al.* Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. *Clin. Cancer Res.* **18**, 2515–2525 (2012).
- Fordyce, S.L. *et al.* Genetic diversity among pandemic 2009 influenza viruses isolated from a transmission chain. *Virology*. **10**, 116 (2013).
- Roth, A.D. *et al.* Prognostic role of *KRAS* and *BRAF* in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. *J. Clin. Oncol.* **28**, 466–474 (2010).
- Planchard, D. *et al.* Interim results of phase II study BRF113928 of dabrafenib in *BRAF* V600E mutation-positive non-small cell lung cancer (NSCLC) patients. *J. Clin. Oncol.* **31**, 2013 (suppl; abstract 8009) (2013).
- Lin, L. *et al.* Mapping the molecular determinants of *BRAF* oncogene dependence in human lung cancer. *Proc. Natl. Acad. Sci. USA* **111**, E748–E757 (2014).
- Prahallad, A. *et al.* Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. *Nature* **483**, 100–103 (2012).
- Corcoran, R.B. *et al.* EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. *Cancer Discov.* **2**, 227–235 (2012).
- Montero-Conde, C. *et al.* Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in *BRAF*-mutant thyroid carcinomas. *Cancer Discov.* **3**, 520–533 (2013).
- Rudin, C.M., Hong, K. & Streit, M. Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer. *J. Thorac. Oncol.* **8**, e41–e42 (2013).
- Downward, J. Targeting RAS signalling pathways in cancer therapy. *Nat. Rev. Cancer* **3**, 11–22 (2003).
- Young, A. *et al.* Ras signaling and therapies. *Adv. Cancer Res.* **102**, 1–17 (2009).
- Bivona, T.G. *et al.* FAS and NF- κ B signalling modulate dependence of lung cancers on mutant EGFR. *Nature* **471**, 523–526 (2011).
- Hong, W. & Guan, K.L. The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. *Semin. Cell Dev. Biol.* **23**, 785–793 (2012).
- Pan, D. The hippo signaling pathway in development and cancer. *Dev. Cell* **19**, 491–505 (2010).
- Pylyayeva-Gupta, Y., Grabocka, E. & Bar-Sagi, D. RAS oncogenes: weaving a tumorigenic web. *Nat. Rev. Cancer* **11**, 761–774 (2011).
- Kapoor, A. *et al.* Yap1 activation enables bypass of oncogenic *Kras* addiction in pancreatic cancer. *Cell* **158**, 185–197 (2014).
- Zhang, W. *et al.* Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. *Sci. Signal.* **7**, ra42 (2014).
- Shao, D.D. *et al.* KRAS and YAP1 converge to regulate EMT and tumor survival. *Cell* **158**, 171–184 (2014).
- Huang, J., Wu, S., Barrera, J., Matthews, K. & Pan, D. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the *Drosophila* homolog of YAP. *Cell* **122**, 421–434 (2005).
- Vigneron, A.M., Ludwig, R.L. & Vousden, K.H. Cytoplasmic ASPP1 inhibits apoptosis through the control of YAP. *Genes Dev.* **24**, 2430–2439 (2010).
- Rosenbluh, J. *et al.* β -catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. *Cell* **151**, 1457–1473 (2012).
- Frederick, D.T. *et al.* Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting *de novo* resistance using BH3 mimetics. *PLoS ONE* **9**, e101286 (2014).
- Corcoran, R.B. *et al.* Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. *Cancer Cell* **23**, 121–128 (2013).
- Tan, N. *et al.* Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models. *Mol. Cancer Ther.* **12**, 853–864 (2013).
- Feng, X. *et al.* Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated Rho GTPase signaling circuitry. *Cancer Cell* **25**, 831–845 (2014).
- Yu, F.X. *et al.* Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. *Cancer Cell* **25**, 822–830 (2014).

ONLINE METHODS

Cell lines and culture reagents. The HCC364 cell line was kindly provided by D. Solit (Memorial Sloan Kettering Cancer Center). MM415 and SKMEL-2 cells were kindly provided by B. Bastian (University of California, San Francisco). WM793, HPAF-II and PANC 02.03 cells were kindly provided by E. Collisson (University of California, San Francisco). CAL-12T, A2058, HT29, WiDr, A549, Calu-1, H23, SW1573 and H2347 cells were purchased from the American Type Culture Collection (ATCC). HTC-C3 cells were purchased from Deutsche Sammlung von Mikroorganismen und Zellkulturen (DMSZ), Germany. KHM-5M cells were purchased from the Japanese Collection of Research Bioresources (JCRB). MOR/CPR cells were purchased from Sigma. Cells were maintained at 37 °C in a humidified atmosphere at 5% CO₂, grown in RPMI 1640 supplemented with 10% FBS, 100 IU/ml penicillin and 100 µg/ml streptomycin. All cell lines used tested negative for mycoplasma.

Compounds. Vemurafenib, trametinib, TW37 and ABT-263 were purchased from Sellekchem. PLX4720 was kindly provided by Plexxikon.

shRNA screen with the DECIPHER shRNA library. Lentiviral plasmids encoding shRNAs including the Collecta DECIPHER shRNA library human module 1 are described online at the company's website. shRNA lentiviruses were generated from HEK293FT cells according to the manufacturer's protocol (Collecta). HCC364 cells were infected with lentiviral supernatant containing shRNAs with a multiplicity of infection (MOI) of 0.3. After 48 h, the infection rate was measured by flow cytometry, and cells were replated with medium containing 1 µg/ml puromycin. Seventy-two hours after the addition of puromycin, 27 million cells were frozen for further analysis, and 27 million cells were replated in the presence and absence of 1 µM or 3 µM vemurafenib; the medium was refreshed every 3 d for 10 d. Genomic DNA was isolated, and shRNA inserts were retrieved according to the manufacturer's protocol (Collecta). Indexes and adaptors for deep sequencing were incorporated into PCR primers. Sample quantification was performed on a Bioanalyzer (Agilent Technologies) to ensure that samples were pooled at the same quantity. Deep sequencing was performed using the Illumina HiSeq 2500 platform at the Center for Advanced Technology of the University of California, San Francisco. shRNA barcodes were segregated and deconvoluted from each sequencing read. *P* values for each gene were calculated as follows. For each gene *G* with *k* barcodes, each with shRNA count *c* in the control condition and *d* in the experimental condition, a test statistic *r*(*G*) was computed as the second lowest ranked value of

$$t_i(G) = \log_2 \left(\frac{d_i(G)}{c_i(G)} \right), i \text{ in } (1, k)$$

Subsequently, a *P* value was computed on the basis of *r*(*G*) as

$$P(G) = \sum_{i=1}^N q_i$$

where

$$q_i = \begin{cases} 0 & \text{if } s_i(k) \leq r(G) \\ 1 & \text{if } s_i(k) > r(G) \end{cases}$$

and *s*(*k*) is the second lowest ranked value of *k* randomly chosen values *t* from all barcodes in all genes and *N* is the number of permutation trials performed. For this sample, we set *N* at 10,000. Individual shRNAs used for the validation experiments were purchased from Sigma.

Cell viability assays. Cells (3,000–5,000) were plated per well in 96-well plates 24 h before drug treatment. The number of viable cells was determined 72 h after the initiation of drug treatment using CellTiter-Glo luminescent cell viability reagent according to the manufacturer's protocol (Promega). Each assay consisted of four replicate wells and was repeated at least three times. Data are expressed as percentage of the cell viability of control cells. Data were graphically displayed using GraphPad Prism version 5.0 for Mac (GraphPad Software).

IC₅₀ values were calculated as 50% of growth inhibition as measured by the cell viability assays. Maximal growth inhibition was calculated as the maximum percentage of growth inhibition achieved upon trametinib treatment from 0.1 nM to 1,000 nM, as measured by the cell viability assays.

Apoptosis assays. Cells (7,500–10,000) were plated per well in 96-well white plates 24 h before drug treatment. The proportion of apoptotic cells was determined 24 h after the initiation of drug treatment using Caspase3/7-Glo luminescent assay reagent according to the manufacturer's protocols (Promega). Each assay consisted of four replicate wells and was repeated at least three times. Data are expressed as percentage of the cell viability of control cells. Data were graphically displayed using GraphPad Prism version 5.0 for Mac (GraphPad Software).

Quantitative PCR. Total RNA was collected from cultured cells using the RNeasy kit (Qiagen). cDNA was synthesized with SuperScript III reverse transcriptase using random hexamer primers (Invitrogen), and RT-PCR was performed on a QuantStudio instrument with TaqMan probes (Life Technologies), using the following program: holding at 50 °C for 2 min and polymerase activation at 95 °C for 20 s, followed by 40 cycles of amplification (95 °C for 1 s, 60 °C for 20 s). *TBP* expression was used as an internal reference to normalize input cDNA. Ratios of the expression level of each gene to that of the reference gene were then calculated.

Protein blot analysis. Cells (200,000) were seeded per well in 6-well plates 24 h before drug treatment, and whole-cell lysates were prepared using RIPA buffer (10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl) supplemented with protease inhibitor and phosphatase inhibitor (Roche) and clarified by sonication and centrifugation. Nuclear and cytosol fractionation was performed using NE-PER nuclear and cytoplasmic extraction reagents (Thermo). Equal amounts of protein were separated by 4–15% SDS-PAGE and were transferred onto nitrocellulose membranes (Bio-Rad) for protein blot analysis. Membranes were incubated with primary antibody overnight, washed and incubated with secondary antibody. Membranes were exposed using either a fluorescence system (Li-Cor) or a chemiluminescent reagent; images were captured, and bands were quantified using an ImageQuant LAS 4000 instrument (GE Healthcare).

Antibodies. Antibodies to YAP/TAZ (8418), Parp (9542) and Bcl-xL (2764) were purchased from Cell Signaling Technology. Antibodies to YAP (sc-101199) and GAPDH (sc-59540) for protein blotting were purchased from Santa Cruz Biotechnology. The antibody to YAP (sc-15407) for immunohistochemistry was purchased from Santa Cruz Biotechnology. The antibody to β-actin (A2228) was purchased from Sigma-Aldrich.

Tumor xenograft study. Each indicated cell line (A2058, HT29 and MOR/CPR) was infected with lentiviruses encoding either scrambled control shRNA or *YAP1* shRNA was injected subcutaneously into the left and right posterior flanks of 7-week-old immunodeficient NOD-SCID female mice (Charles River). Tumor formation was measured twice a week, and tumor volumes were calculated by length × width × height. When the tumor reached approximately 200–300 mm³, the mice were randomized for drug treatments (PLX4720, 50 mg/kg; trametinib, 1 mg/kg). The fold change in tumor volume was normalized to the tumor volume when treatments were initiated for each tumor. The duration of treatment was 14 d for A2058 and MOR/CPR and 21 d for HT29 tumor xenografts. All mouse experiments were performed in accordance with protocols approved by the University of California at San Francisco Institutional Animal Care and Use Committee. Sample size was not predetermined.

Immunohistochemical analyses of human tumor specimens. All specimens were acquired from individuals with NSCLC and melanoma under the auspices of institutional review board (IRB)-approved clinical protocols at each hospital in which informed consent was obtained. *BRAF* and *KRAS* mutation status was assessed by established clinical DNA sequencing assays. Immunohistochemistry for YAP (H-125, Santa Cruz Biotechnology) was conducted on formalin-fixed, paraffin-embedded tumor sections as previously described^{33,34}. Statistical significance was assessed and is reported as the *P* value from the χ² test, with *P* < 0.05 considered significant.

RNA deep sequencing and analysis. RNA from each of the indicated cell lines was extracted by RNeasy kit (Qiagen). In total, 2 µg of total RNA was used for deep sequencing library preparation using Illumina TruSeq sample prep kits according to the manufacturer's protocols. Sequencing libraries with different indices were pooled and sequenced in paired-end format to a length of 100 bp using the HiSeq 2500 platform at the Center for Advanced Technology at the University of California, San Francisco. Reads were aligned against NCBI Build 37 (hg19) of the human genome using NCBI Ensembl transcript annotation (version 75) with RSEM³⁵, which also yielded gene-level quantification of expression.

Differential expression and pathway analysis. Differential gene expression analysis was performed with DESeq³⁶ among three sets of conditions: (i) *YAP1* knockdown using two independent validated shRNAs, (ii) shSCR (scrambled shRNA control) and trametinib (100 nM), and (iii) *YAP1* knockdown using two independent shRNAs and trametinib (100 nM), each compared to the

control condition (shSCR and DMSO). Pathway analysis (gene set enrichment) was performed on genes significantly differentially expressed ($q < 0.05$) that were exclusive to the *YAP1* knockdown and trametinib treatment condition, using MSigDB³⁷.

33. Hall, C.A. *et al.* Hippo pathway effector Yap is an ovarian cancer oncogene. *Cancer Res.* **70**, 8517–8525 (2010).
34. Zhao, B. *et al.* Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. *Genes Dev.* **21**, 2747–2761 (2007).
35. Li, B. & Dewey, C.N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. *BMC Bioinformatics* **12**, 323 (2011).
36. Anders, S. & Huber, W. Differential expression analysis for sequence count data. *Genome Biol.* **11**, R106 (2010).
37. Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. USA* **102**, 15545–15550 (2005).